4th iPSC Drug Development and Manufacturing Summit

Temi della conferenza
With Kenai Therapeutics emerging from stealth with an $82 Million Series A funding round, 2024 has started strong for iPSC drug developers looking to showcase the potential of their pipelines ahead of the next wave of investment.

Professional congress organizer (PCO)
Hanson Wade

Annotazioni
Brochure: https://go.evvnt.com/2453698-3?pid=4832

Speakers: Allen Feng, Founder & Chief Scientific Officer, HebeCell, Anne Plant, Fellow Chief, Biosystems and Biomaterials Division, National Institute of Standards & Technology (NIST), and more

https://go.evvnt.com/2453698-2?pid=4832

Ms. Lara Chick